FDA approves new pancreatic cancer drug

October 22, 2015

FDA approves new pancreatic cancer drug
Agency says medication can be used in combination with others for advanced cases.
(HealthDay)—The U.S. Food and Drug Administration has approved a new drug called Onivyde as part of a treatment regimen for advanced pancreatic cancer.

Onivyde (irinotecan liposome injection) was approved to be used in combination with fluorouracil and leucovorin. The combination was approved for use in patients with advanced who were already treated with gemcitabine-based chemotherapy, the FDA said Thursday in a news release.

The approval was based on a study of more than 400 patients. All had experienced cancer growth despite gemcitabine-based chemotherapy. The new research included three treatment arms. Patients were randomly assigned to receive Onivyde with fluorouracil/leucovorin, Onivyde alone, or fluorouracil/leucovorin alone.

The researchers found that people treated with Onivyde plus fluorouracil/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only fluorouracil/leucovorin, the FDA said.

But, there was no survival benefit for patients who received Onivyde alone compared to those who received only fluorouracil/leucovorin, the findings showed.

The study also found that the average amount of time to tumor growth was 3.1 months for patients who received Onivyde plus fluorouracil/leucovorin compared to 1.5 for those who received only fluorouracil/leucovorin.

The most common side effects of Onivyde were diarrhea, fatigue, vomiting, nausea, decreased appetite, inflammation in the mouth and fever, the researchers said.

The drug also led to low counts of infection-fighting cells (lymphopenia and neutropenia). The FDA also said that death due to sepsis—a severe inflammatory response triggered by infection—following neutropenia has been reported in taking Onivyde.

Onivyde's label carries a boxed warning about the risks of severe neutropenia and diarrhea. The is marketed by Merrimack Pharmaceuticals Inc., of Cambridge, Mass.

Nearly 49,000 new cases of pancreatic cancer will be diagnosed in the United States this year and there will be more than 40,500 deaths from the disease, according to the U.S. National Cancer Institute.

Pancreatic cancer is difficult to diagnose early and there are limited treatment options, especially when it has spread to other parts of the body and surgery to remove the tumor is not possible, the FDA said in the news release.

Explore further: MM-398 added to standard treatment shows survival benefit in mets pancreatic cancer

More information: The U.S. National Cancer Institute has more about pancreatic cancer.

Related Stories

MM-398 added to standard treatment shows survival benefit in mets pancreatic cancer

June 25, 2014
Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer ...

New therapy for pancreatic cancer patients shows promising results

June 5, 2014
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug ...

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

October 23, 2014
(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, leucovorin, ...

After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose

September 7, 2010
Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who ...

FDA approves expanded use of Opdivo in advanced lung cancer

October 12, 2015
(HealthDay)—The U.S. Food and Drug Administration has approved Opdivo (nivolumab) to treat patients with advanced non-small-cell lung cancer (NSCLC) whose disease progressed despite platinum-based chemotherapy.

Lonsurf approved for advanced colon cancer

September 23, 2015
(HealthDay)—The combination pill Lonsurf (trifluridine and tipiracil) has been approved by the U.S. Food and Drug Administration to treat advanced colon cancer for people who aren't responding to other treatments, the agency ...

Recommended for you

Pancreatic cancer's addiction could be its end

November 13, 2018
Cancer cells are often described as cells "gone bad" or "renegade." New research reveals that in some of the deadliest cases of pancreatic cancer, these rebellious cells have an unexpected addiction. Now, scientists are investigating ...

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

Study finds promising therapeutic target for aggressive type of breast cancer

November 13, 2018
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative ...

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.